Integrated Drug Development
Our Integrated Drug Development work aims to increase the speed and reliability of delivering innovative dementia medicines and to increase patients’ access to medicines, treatments and health technologies across the world.
Global Team Lead: Raj Long
Team Members: Kiki Edwards; Dr. Kiyoshi Kurakawa; George Vradenburg; Johannes Levin; Megan Zoschg-Canniere
Aims of the group
- To increase the speed and reliability of the delivery of new dementia medicines, through creating an efficient and effective global treatment development pathway.
- To increase patients’ access to dementia medicines, treatments and health technologies across the world.
Current work priorities
- Identifying and engaging with key bodies that provide funds for, commission and/or enable access to dementia medicines and health technologies across the world (e.g. NICE in the UK).
- Working with these bodies to develop and implement a global plan for developing effective dementia treatments and innovations.